



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/178740/2024

## European Medicines Agency decision P/0166/2024

of 6 May 2024

on the granting of a product specific waiver for amivantamab (Rybrevant), (EMEA-002573-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Only the English text is authentic.**



# European Medicines Agency decision

P/0166/2024

of 6 May 2024

on the granting of a product specific waiver for amivantamab (Rybrevant), (EMA-002573-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Janssen-Cilag International N.V. on 15 December 2023 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 22 March 2024 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

**Article 1**

A waiver for amivantamab (Rybrevant), all pharmaceutical forms, all routes of administration, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 2**

This decision is addressed to Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium.

EMA/PDCO/27577/2024  
Amsterdam, 22 March 2024

## Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-002573-PIP02-23

### Scope of the application

**Active substance(s):**

Amivantamab

**Invented name and authorisation status:**

See Annex II

**Condition(s):**

Treatment of colorectal carcinoma

**Pharmaceutical form(s):**

All pharmaceutical forms

**Route(s) of administration:**

All routes of administration

**Name/corporate name of the PIP applicant:**

Janssen-Cilag International N.V.

### Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International N.V. submitted to the European Medicines Agency on 15 December 2023 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 22 January 2024.

## Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with

Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

## **Annex I**

### **Grounds for the granting of the waiver**

# 1. Waiver

## **1.1. Condition:**

Treatment of colorectal carcinoma

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- all pharmaceutical forms, all routes of administration;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

## **Annex II**

### **Information about the authorised medicinal product**



***Information provided by the applicant:***

**Condition(s) and authorised indication(s)**

1. Treatment of non-small cell lung cancer (NSCLC)

Authorised indication(s):

- Rybrevant as monotherapy is indicated for treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations, after failure of platinum-based therapy.
  - Invented name(s): Rybrevant
  - Authorised pharmaceutical form(s): concentrate for solution for infusion
  - Authorised route(s) of administration: intravenous use
  - Authorised via centralised procedure